Article CommentaryCommentary

Probability Concepts in Quality Risk Management

H. Gregg Claycamp
PDA Journal of Pharmaceutical Science and Technology January 2012, 66 (1) 78-89; DOI: https://doi.org/10.5731/pdajpst.2012.00801

References

  1. 1.↵
    1. Mlodinow L.
    The Drunkard's Walk: How Randomness Rules Our Lives; Vintage Books: New York, 2008.
  2. 2.↵
    1. Singpurwalla N. D.,
    2. Wilson A. G.
    Probability, chance and the probability of chance. IIE Transactions 2009, 41 (1),12–22.
    OpenUrl
  3. 3.↵
    1. Bernstein P.
    Against the Gods. The Remarkable Story of Risk; John Wiley & Sons: New York, 1996.
  4. 4.↵
    1. Visschers V. H.,
    2. Meertens R. M.,
    3. Passchier W. W.,
    4. de Vries N. N.
    Probability information in risk communication: a review of the research literature. Risk Anal. 2009, 29 (2),267–287.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Gigerenzer G.,
    2. Hertwig R.,
    3. van den Broek E.,
    4. Fasolo B.,
    5. Katsikopoulos K. V.
    “A 30% chance of rain tomorrow”: How does the public understand probabilistic weather forecasts? Risk Anal. 2005, 25 (3),623–629.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Pearl J.
    Causality: Models, Reasoning and Inference; Cambridge University Press: Cambridge, UK, 2000.
  7. 7.↵
    1. Anonymous
    . “Common Cause and Special Cause”; wikipedia.org. http://en.wikipedia.org/wiki/Common_cause_and_special_cause (accessed March 21, 2011).
  8. 8.↵
    1. Ayyub B. M.
    Risk Analysis in Engineering and Economics; Chapman and Hall/CRC: Boca Raton, FL, 2003.
  9. 9.↵
    1. Kaplan S.,
    2. Garrick B. J.
    On the quantitative definition of risk. Risk Anal. 1981, 1 (1),11–27.
    OpenUrlCrossRef
  10. 10.↵
    Quality Risk Management Q9, ICH Harmonised Tripartite Guideline. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 2005. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf (accessed April 19, 2011).
  11. 11.↵
    Food and Drug Administration (FDA). Guidance for Industry Q9 Quality Risk Management. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), 2006.
  12. 12.↵
    International Standards Organization (ISO). Application of Risk Management to Medical Devices,International Standard ISO14971:2000.
  13. 13.↵
    ISO. Risk Management—Principles and Guidelines. International Standard ISO 31000:2009(E).
  14. 14.↵
    1. Aven T.,
    2. Renn O.
    On risk defined as an event where the outcome is uncertain. J. Risk Res. 2009, 12 (1),1–11.
    OpenUrlCrossRefWeb of Science
  15. 15.↵
    1. Hubbard D. G.
    How to Measure Anything; Wiley: New York, 2007.
  16. 16.↵
    1. Savage S. L.
    The Flaw of Averages: Why We Underestimate Risk in the Face of Uncertainty; John Wiley & Sons: Hoboken, NJ, 2009.
  17. 17.↵
    1. Keeney R.
    Making better decision makers. Decision Anal. 2004, 1 (4),193–204.
    OpenUrlCrossRef
  18. 18.↵
    1. Kahneman D.,
    2. Slovic P.,
    3. Tversky A.
    Judgment under Uncertainty: Heuristics and Biases; Cambridge University Press: Cambridge, UK, 1982.
  19. 19.↵
    1. Mauboussin M. J.
    Think Twice: Harnessing the Power of Counterintuition; Harvard Business Press: Boston, 2009.
  20. 20.↵
    1. Ariely D.
    Predictably Irrational: The Hidden Forces that Shape Our Decisions; Harper-Collins: New York, 2008.
  21. 21.↵
    1. Hubbard D. L.
    The Failure of Risk Management: Why It's Broken and How to Fix It; John Wiley & Sons: Hoboken, NJ, 2009.
  22. 22.↵
    1. Jaffe J.,
    2. Stavins R. N.
    On the value of formal assessment of uncertainty in regulatory analysis. Regulation & Governance 2007, 1 (2),154–171.
    OpenUrl
  23. 23.↵
    1. Morgan M. G.,
    2. Henrion M.
    Uncertainty: A Guide to Dealing with Uncertainty in Quantitative Risk and Policy Analysis; Cambridge University Press: Cambridge, UK, 1990.
  24. 24.↵
    1. Keeney R. L.
    Value-Focused Thinking; Cambridge University Press: Cambridge, UK, 1992.
  25. 25.↵
    1. Thornton A. C.
    Variation Risk Management. John Wiley & Sons: Hoboken, NJ, 2004.
  26. 26.↵
    1. Claycamp H. G.
    Risk, uncertainty, and process analytical technology. J. Process Anal. Technol. 2006, 3 (2),8–12.
    OpenUrl
  27. 27.↵
    ICH. Pharmaceutical Development Q8(R2), ICH Harmonised Tripartite Guideline, Current Step 4 version, August 2009. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html (accessed July 20, 2011).
  28. 28.↵
    ICH. Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities), Draft Consensus Guideline, Current Step 2 version, May 2011. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html (accessed July 20, 2011).
  29. 29.↵
    1. Harry M.,
    2. Schroeder R.
    Six Sigma: The Breakthrough Management Strategy Revolutionizing the World's Top Corporations; Currency Press: New York, 2000.
  30. 30.↵
    1. Vose D.
    Risk Analysis: A Quantitative Guide, 2nd ed.; John Wiley & Sons: Chichester, UK, 2000.
  31. 31.↵
    1. Claycamp H. G.
    . Perspective on quality risk management of pharmaceutical quality. Drug Information J. 2007, 41 (3),353–367.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Haimes Y. Y.
    Risk Modeling, Assessment, and Management; John Wiley & Sons: New York, 2004.
  33. 33.↵
    1. Linkov I.,
    2. Satterstrom F. K.,
    3. Kiker G.,
    4. Batchelor C.,
    5. Bridges T.,
    6. Ferguson E.
    Comparative risk assessment to multi-criteria decision analysis and adaptive management: recent developments and applications. Environ. Int. 2006, 32 (8),1072–1093.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Haimes Y. Y.,
    2. Kaplan S.,
    3. Lambert J. H.
    Risk filtering, ranking, and management framework using hierarchical holographic modeling. Risk Anal. 2002, 22 (2),383–397.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Morgan G. M.,
    2. Florig H. K.,
    3. DeKay M. L.,
    4. Fischbeck P.
    Categorizing risks for risk ranking. Risk Anal. 2000, 20 (1),49–58.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. O'Hagan A.,
    2. Buck C. E.,
    3. Daneshkhah A.,
    4. Eiser J. R.,
    5. Garthwaite P. H.,
    6. Jenkinson D. J.,
    7. Oakley J. E.,
    8. Rakow T.
    Uncertain Judgments: Eliciting Experts' Probabilities; John Wiley & Sons: West Sussex, UK, 2006.
  37. 37.↵
    1. Cox L. A. Jr..
    What's wrong with risk matrices? Risk Anal. 2008, 28 (2),497–512.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Taleb N. N.
    The Black Swan: The Impact of the Highly Improbable. Random House: New York, 2007.
  39. 39.↵
    1. Ishikawa K.
    What Is Total Quality Control? The Japanese Way, Lui, D. J., trans.; Prentice-Hall: Englewood Cliffs, NJ, 1985.
  40. 40.↵
    U.S. Department of Energy. DOE Guideline. Root Cause Analysis Guidance Document, Office of Nuclear Energy, Office of Nuclear Energy Safety Policy and Standards: Washington, DC, 1992.
  41. 41.↵
    1. Stamatis D. H.
    Failure Mode and Effect Analysis: FMEA from Theory to Execution, 2nd ed.; ASQ Quality Press: Milwaukee, WI, 2003.
  42. 42.↵
    1. Rönninger S.,
    2. Holmes M.
    A risk-based approach to scheduling audits. PDA J. Pharm. Sci. Technol. 2009, 63 (6),575–588.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Tran N. L.,
    2. Hasselbalch B.,
    3. Morgan K.,
    4. Claycamp G.
    Elicitation of expert knowledge about risks associated with pharmaceutical manufacturing processes. Pharmaceutical Engineering 2005, 25 (4),24–38.
    OpenUrl
  44. 44.↵
    1. Ayyub B. M.
    Elicitation of Expert Opinions for Uncertainty and Risks; CRC Press: Boca Raton, FL, 2001.
  45. 45.↵
    1. Morgan M. G.,
    2. Fischhoff B.,
    3. Bostrom A.,
    4. Atman C. J.
    Risk Communication: A Mental Models Approach; Cambridge University Press: Cambridge, UK, 2002.
  46. 46.↵
    1. Brafman O.
    Sway: The Irresistible Pull of Irrational Behavior; Doubleday: New York, 2008.
  47. 47.↵
    1. Dieckmann N. F.,
    2. Slovic P.,
    3. Peters E. M.
    The use of narrative evidence and explicit likelihood by decisionmakers varying in numeracy. Risk Anal. 2009, 29 (10),1473–1488.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Bond S. D.,
    2. Carlson K. A.,
    3. Keeney R. L.
    Improving the generation of decision objectives. Decision Anal. 2010, 7 (3),238–255.
    OpenUrlCrossRef
Back to top

In This Issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Probability Concepts in Quality Risk Management
H. Gregg Claycamp
PDA Journal of Pharmaceutical Science and Technology Jan 2012, 66 (1) 78-89; DOI: 10.5731/pdajpst.2012.00801
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section